California State Teachers Retirement System Boosts Position in Chemed Co. (CHE) – Fairfield Current

0

California State Teachers Retirement System increased its position in shares of Chemed Co. (NYSE:CHE) by 2.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,420 shares of the company’s stock after acquiring an additional 551 shares during the period. California State Teachers Retirement System owned about 0.15% of Chemed worth $6,918,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of CHE. Vanguard Group Inc. raised its position in Chemed by 2.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,861,197 shares of the company’s stock valued at $594,801,000 after purchasing an additional 35,966 shares in the last quarter. Vanguard Group Inc raised its position in Chemed by 2.0% in the 3rd quarter. Vanguard Group Inc now owns 1,861,197 shares of the company’s stock valued at $594,801,000 after purchasing an additional 35,966 shares in the last quarter. Fisher Asset Management LLC raised its position in Chemed by 0.4% in the 4th quarter. Fisher Asset Management LLC now owns 477,261 shares of the company’s stock valued at $135,198,000 after purchasing an additional 1,961 shares in the last quarter. Investec Asset Management LTD raised its position in Chemed by 7.7% in the 4th quarter. Investec Asset Management LTD now owns 253,517 shares of the company’s stock valued at $71,816,000 after purchasing an additional 18,104 shares in the last quarter. Finally, Renaissance Technologies LLC raised its position in Chemed by 69.5% in the 3rd quarter. Renaissance Technologies LLC now owns 233,690 shares of the company’s stock valued at $74,683,000 after purchasing an additional 95,790 shares in the last quarter. 87.30% of the stock is currently owned by hedge funds and other institutional investors.

CHE stock opened at $321.01 on Friday. The company has a current ratio of 0.83, a quick ratio of 0.80 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $5.13 billion, a price-to-earnings ratio of 26.86, a P/E/G ratio of 1.81 and a beta of 1.21. Chemed Co. has a 1 year low of $260.03 and a 1 year high of $335.99.

Chemed (NYSE:CHE) last posted its quarterly earnings results on Wednesday, February 20th. The company reported $3.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.27 by $0.08. The company had revenue of $457.51 million for the quarter, compared to analyst estimates of $460.50 million. Chemed had a return on equity of 36.06% and a net margin of 11.53%. Chemed’s revenue for the quarter was up 6.8% compared to the same quarter last year. During the same quarter last year, the company earned $2.32 EPS. Equities analysts forecast that Chemed Co. will post 12.77 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, March 22nd. Stockholders of record on Monday, March 4th were given a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a dividend yield of 0.37%. The ex-dividend date of this dividend was Friday, March 1st. Chemed’s dividend payout ratio (DPR) is presently 10.06%.

In other news, VP Michael D. Witzeman sold 735 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $328.00, for a total transaction of $241,080.00. Following the sale, the vice president now owns 4,000 shares of the company’s stock, valued at approximately $1,312,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director George J. Walsh III sold 1,000 shares of the firm’s stock in a transaction dated Monday, February 25th. The stock was sold at an average price of $328.07, for a total value of $328,070.00. Following the sale, the director now directly owns 7,663 shares in the company, valued at approximately $2,514,000.41. The disclosure for this sale can be found here. In the last three months, insiders have bought 36 shares of company stock worth $8,599 and have sold 14,599 shares worth $4,754,381. 4.82% of the stock is currently owned by company insiders.

CHE has been the topic of a number of analyst reports. Zacks Investment Research lowered Chemed from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. Royal Bank of Canada increased their price target on Chemed from $313.00 to $318.00 and gave the company a “sector perform” rating in a research report on Monday, February 25th.

ILLEGAL ACTIVITY NOTICE: “California State Teachers Retirement System Boosts Position in Chemed Co. (CHE)” was originally reported by Fairfield Current and is owned by of Fairfield Current. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://www.fairfieldcurrent.com/news/2019/03/24/california-state-teachers-retirement-system-boosts-position-in-chemed-co-che.html.

Chemed Profile

Chemed Corporation provides hospice and palliative care services in the United States. It operates through two segments, VITAS and Roto-Rooter. The VITAS segment offers direct medical services, as well as spiritual and emotional counseling services to terminally ill patients. This segment offers its services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.

Featured Story: What is the 52-week high/low?

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHE).

Institutional Ownership by Quarter for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Chemed and related companies with MarketBeat.com’s FREE daily email newsletter.

Source

Leave A Reply

Your email address will not be published.